The Role of mTOR (Mammalian Target of Rapamycin) Signaling Pathway in the Antidepressive Effect of Ketamine in Patients with Depressive Disorder

Randomised status: not randomised; single-blind, placebo-controlled crossover design comparing a single intravenous ketamine infusion with a matched placebo infusion in 30 adults with major depressive episode.

Primary outcomes assessed mTOR activity at two hours and 24 hours post-infusion and compared responders (≥50% MADRS reduction at day 1 or day 4) with non-responders; secondary outcomes included changes in functional brain connectivity measured by eLORETA at 30 minutes and 24 hours.